For its generic DIPRIVAN in USA
Claris Lifesciences announced that it has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA, Inc. with reference to the alleged infringement of a patent relating to proposal for injection, 10mg/ml, which is a generic version of Diprivan.Under the terms of the settlement and license agreement, the Claris and Claris Lifesciences Inc. (USA) has been granted approval to sell its generic version of Propofol for injection beginning 15 October 2016 prior to the 01 June 2025 expiry of the patent that formed the basis of the litigation.
Powered by Capital Market - Live News
